About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Why Many At-Risk Patients Are Not Reaching Their Low-density Lipoprotein Cholesterol Goals and the Need for Alternative Therapies

Citation:

European Cardiovascular Disease 2007;3(1):26–8

Hypertension and Diabetes Mellitus

Citation:

European Cardiovascular Disease 2006;2(1):21–4

Low Density Lipoprotein Cholesterol and Coronary Heart Disease - Lower is Better

Citation:

European Cardiology 2005:1(1):1-6